NASDAQ:HTBX - Heat Biologics Stock Price, News, & Analysis

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Heat Biologics's stock reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

Heat Biologics Inc (NASDAQ:HTBX) issued its earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.09. The biopharmaceutical company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.11 million. Heat Biologics had a negative net margin of 437.62% and a negative return on equity of 116.28%. View Heat Biologics' Earnings History.

Heat Biologics is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Heat Biologics.

3 brokerages have issued 1 year price targets for Heat Biologics' shares. Their predictions range from $6.00 to $11.00. On average, they expect Heat Biologics' share price to reach $8.50 in the next year. This suggests a possible upside of 338.1% from the stock's current price. View Analyst Price Targets for Heat Biologics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.

Some companies that are related to Heat Biologics include Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), REDHILL BIOPHAR/S (RDHL), Molecular Templates (MTEM), Calithera Biosciences (CALA), Aldeyra Therapeutics (ALDX), Immune Design (IMDZ), VERONA PHARMA P/S (VRNA), Syndax Pharmaceuticals (SNDX), Avadel Pharmaceuticals (AVDL), Sesen Bio (SESN), BioDelivery Sciences International (BDSI), Eleven Biotherapeutics (EBIO), Tetraphase Pharmaceuticals (TTPH), Spring Bank Pharmaceuticals (SBPH) and Cerecor (CERC).

Headlines about HTBX stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Heat Biologics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Heat Biologics.

Heat Biologics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Northern Trust Corp (0.22%). View Institutional Ownership Trends for Heat Biologics.

HTBX stock was acquired by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for Heat Biologics.

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HTBX stock can currently be purchased for approximately $1.94.

Heat Biologics has a market capitalization of $43.25 million and generates $1.51 million in revenue each year. Heat Biologics employs 19 workers across the globe.

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]